[Human testing of the nuclear spin tomographic contrast medium gadolinium-DTPA. Tolerance, contrast affect and the 1st clinical results]. 1984

W Schörner, and R Felix, and M Laniado, and L Lange, and H J Weinmann, and C Claussen, and W Fiegler, and U Speck, and E Kazner

In an initial clinical trial we examined the tolerance and the influence exercised on signals in nuclear magnetic resonance tomography by gadolinium-DTPA. In an open study, 4 dosages between 0.005 and 0.25 mmol Gd-DTPA/kg body-weight were tested on 5 healthy volunteers each. To ensure renal elimination of Gd-DTPA, NMR images were produced (0.35 T Magnetom) visualising the kidneys and urinary bladder before and more than 60 minutes after application of the contrast medium. The article shows in what manner the image is influenced by the dosage of the contrast medium and also by the time interval elapsing between injection of the contrast medium and production of the NMR tomogram. - Finally, first clinical results of NMR tomography contrast medium application are demonstrated in the case of 5 patients with cerebral tumours.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D001743 Urinary Bladder A musculomembranous sac along the URINARY TRACT. URINE flows from the KIDNEYS into the bladder via the ureters (URETER), and is held there until URINATION. Bladder,Bladder Detrusor Muscle,Detrusor Urinae,Bladder Detrusor Muscles,Bladder, Urinary,Detrusor Muscle, Bladder,Detrusor Muscles, Bladder
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003287 Contrast Media Substances used to allow enhanced visualization of tissues. Radiopaque Media,Contrast Agent,Contrast Agents,Contrast Material,Contrast Materials,Radiocontrast Agent,Radiocontrast Agents,Radiocontrast Media,Agent, Contrast,Agent, Radiocontrast,Agents, Contrast,Agents, Radiocontrast,Material, Contrast,Materials, Contrast,Media, Contrast,Media, Radiocontrast,Media, Radiopaque
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug

Related Publications

W Schörner, and R Felix, and M Laniado, and L Lange, and H J Weinmann, and C Claussen, and W Fiegler, and U Speck, and E Kazner
August 2000, The British journal of radiology,
W Schörner, and R Felix, and M Laniado, and L Lange, and H J Weinmann, and C Claussen, and W Fiegler, and U Speck, and E Kazner
December 1997, Rontgenpraxis; Zeitschrift fur radiologische Technik,
W Schörner, and R Felix, and M Laniado, and L Lange, and H J Weinmann, and C Claussen, and W Fiegler, and U Speck, and E Kazner
November 1995, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin,
W Schörner, and R Felix, and M Laniado, and L Lange, and H J Weinmann, and C Claussen, and W Fiegler, and U Speck, and E Kazner
November 1987, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin,
W Schörner, and R Felix, and M Laniado, and L Lange, and H J Weinmann, and C Claussen, and W Fiegler, and U Speck, and E Kazner
July 1985, Rontgenpraxis; Zeitschrift fur radiologische Technik,
W Schörner, and R Felix, and M Laniado, and L Lange, and H J Weinmann, and C Claussen, and W Fiegler, and U Speck, and E Kazner
March 1994, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin,
W Schörner, and R Felix, and M Laniado, and L Lange, and H J Weinmann, and C Claussen, and W Fiegler, and U Speck, and E Kazner
December 1986, Digitale Bilddiagnostik,
W Schörner, and R Felix, and M Laniado, and L Lange, and H J Weinmann, and C Claussen, and W Fiegler, and U Speck, and E Kazner
December 1986, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin,
W Schörner, and R Felix, and M Laniado, and L Lange, and H J Weinmann, and C Claussen, and W Fiegler, and U Speck, and E Kazner
June 2014, Plastic and reconstructive surgery,
W Schörner, and R Felix, and M Laniado, and L Lange, and H J Weinmann, and C Claussen, and W Fiegler, and U Speck, and E Kazner
January 1989, Radiologia diagnostica,
Copied contents to your clipboard!